Regulatory & Enforcement
The FDA is intensifying its scrutiny of compounding pharmacies producing popular weight-loss medications. Recent inspections revealed evidence that a compounding facility was regularly manufacturing versions of Eli Lilly's tirzepatide and Novo Nordisk's semaglutide under conditions that pose a risk of contaminating the drugs "with filth" FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’.
In a related enforcement action, the agency issued a warning letter to Empower Pharmacy, citing violations of federal law related to the illegal mass production of compounded GLP-1 drugs FDA Warns Pharmacy About Illegal GLP-1 Compounding. These actions underscore the agency's growing focus on the safety and legality of compounded alternatives to blockbuster metabolic therapies Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know..
Compliance Takeaway
As the FDA aggressively targets compounding pharmacies over contamination risks and mass production of GLP-1 analogs, research peptide suppliers must maintain rigorous quality control and strict adherence to "Research Use Only" (RUO) labeling. The heightened regulatory environment increases the risk that enforcement sweeps could inadvertently impact the broader peptide supply chain if facilities fail to clearly delineate their operations from clinical compounding.